Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2023 Dec 2;10(12):ofad604.
doi: 10.1093/ofid/ofad604. eCollection 2023 Dec.

Long-Acting Cabotegravir/Rilpivirine Concentrations in Combination With Intravenous Rifampin: A Case Report

Shawnalyn W Sunagawa  1 , Joshua P Havens  1   2 , Anthony Podany  1 , Bryan Walker  2 , Kimberly K Scarsi  1   2 , Sara H Bares  2
Affiliations

Long-Acting Cabotegravir/Rilpivirine Concentrations in Combination With Intravenous Rifampin: A Case Report

Shawnalyn W Sunagawa et al. Open Forum Infect Dis. .

Abstract

As antiretroviral therapy advancements focus on long-acting medications, there is a need to assess the potential impact of drug-drug interactions. We present a real-world case of long-acting cabotegravir/rilpivirine co-administered with intravenous rifampin. The combination resulted in both cabotegravir and rilpivirine concentrations falling below 4 times the protein-adjusted IC90.

Keywords: drug-drug interactions; long-acting cabotegravir/rilpivirine; plasma concentrations; rifamycins.

PubMed Disclaimer

Conflict of interest statement

Potential conflicts of interest. J.H.: investigator-initiated grant support paid to his institution from Gilead Sciences as well as participation on a scientific advisory board for ViiV Health Care. K.S.: investigator-initiated grant support paid to her institution from Organon, LLC. S.H.B.: research grants to her institution from ViiV Health Care and Janssen as well as participation on a scientific advisory board for Gilead Sciences. All the other authors report no conflicts of interest/disclosures relevant to this article.

Figures

Figure 1.
Figure 1.
Anti-infective and pharmacokinetic concentration time course. aLA CAB/RPV was administered on hospital day #39 at 1800, PK concentrations obtained on hospital day #46 at 1000. bBoth DTG and TDF/FTC were administered via nasogastric tube as a trial to determine if the patient could tolerate enteral medications; all other medications were administered parenterally. Abbreviations: BID, twice daily; DTG, dolutegravir; LAI CAB/RPV, long-acting injectable cabotegravir/rilpivirine; PK, pharmacokinetic; TDF/FTC, tenofovir disoproxil fumarate/emtricitabine.
See this image and copyright information in PMC

References

    1. Panel on Guidelines for the Prevention and Treatment of Opportunistic Infections in Adults and Adolescents with HIV, National Institutes of Health, Centers for Disease Control and Prevention, HIV Medicine Association, and Infectious Diseases Society of America . Guidelines for the prevention and treatment of opportunistic infections in adults and adolescents with HIV. Available at: https://clinicalinfo.hiv.gov/en/guidelines/adult-and-adolescent-opportun.... Accessed 24 June 2023.
    1. Torok ME, Yen NT, Chau TT, et al. Timing of initiation of antiretroviral therapy in human immunodeficiency virus (HIV)-associated tuberculosis meningitis. Clin Infect Dis 2011; 52:1374–83. - PMC - PubMed
    1. Ford SL, Sutton K, Lou Y, et al. Effect of rifampin on the single-dose pharmacokinetics of oral cabotegravir in healthy subjects. Antimicrob Agents Chemother 2017; 61:e00487-17. - PMC - PubMed
    1. US Food and Drug Administration . Cabenuva product label. Available at: https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/212888s000lbl.pdf. Accessed 6 July 2023.
    1. Heartland National TB Center . Available at: https://www.heartlandntbc.org. Accessed 7 July 2023.